In treating HER2-positive breast cancer, targeted therapy is recommended using HER2 inhibitors combined with chemotherapy regardless of disease stage [8], with well-established efficacy [5,6,7,9,10,11,12,13,14]. The gene discussed is ERBB2; the disease is breast cancer.